StockNews.AI
LUCD
StockNews.AI
4 hrs

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

1. Lucid Diagnostics will host a conference call on September 8, 2025. 2. The call will discuss the recent CAC Meeting regarding a Local Coverage Determination. 3. This review is crucial for Lucid's EsoGuard DNA Test coverage. 4. Lucid is focused on early detection of esophageal precancer and cancer. 5. Investor interest may spike before and after the conference call.

11m saved
Insight
Article

FAQ

Why Bullish?

The discussion on LCD L39256 could indicate potential product reimbursement, boosting investor confidence. Similar past events that positively altered stock prices serve as reference points.

How important is it?

The article fundamentally discusses Lucid’s leadership and strategy impacting future product uptake, which is crucial for stock performance.

Why Short Term?

Investor sentiment may shift immediately surrounding the conference call and announcements. Historically, short-term price movements often follow such events.

Related Companies

Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia," for Lucid's EsoGuard® Esophageal DNA Test.

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.

Webcast and Conference Call Details

Date: Monday, September 8, 2025

Time: 8:30 AM ET

WebcastClick Here to Join

The webcast will also be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Investor Call" to join.

Following the conclusion of the call, a replay will be available for 90 days on the Company's investor relations website.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Cision View original content:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-host-investor-call-on-monday-september-8-2025-302547258.html

SOURCE Lucid Diagnostics

Related News